Loading stock data…
Alkermes plc (ALKS)
$52.70-2.38 (-4.31%)
Market OpenUpdated 3:09 PM EDT
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alkermes plc in the Healthcare sector is trading at $52.98 with a market capitalization of $7.1B. Wall Street consensus targets $48.12 (16 analysts), implying a -9.2% move over the next 12 months. The stock is currently near its 52-week high of $55.28, remaining 61.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -9.2% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $392.91M↑ | $384.55M↓ | $394.19M↑ | $390.66M↑ | $306.51M |
| Gross Profit | $331.33M↓ | $338.34M↓ | $342.59M↑ | $341.20M↑ | $257.31M |
| Operating Income | -$48.28M↓ | $58.10M↓ | $89.08M↓ | $92.98M↑ | $13.79M |
| Net Income | -$66.48M↓ | $49.34M↓ | $82.76M↓ | $87.10M↑ | $22.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.13B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
47.51
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.72%
Volume
Today's trading volume
1.64M
Recent News
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Investing.com -- Bank of America downgraded four U.S. biopharmaceutical companies, lowering ratings on Alkermes, Amphastar Pharmaceuticals and Biohaven to Underperform, while cutting Liquidia to Neutral, citing a combination of stretched valuations, uncertain near-term catalysts and a rebalancing of its ratings across the sector.
Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says
Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin
Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls
Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls
Here Are Monday’s Best Wall Street Analyst Research Calls: Adobe, Applovin, Casey’s General Stores, CrowdStrike, Honeywell Aerospace, Salesforce, Synaptics, Terawulf, and More
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week, with the Federal 4th of July holiday scheduled for Friday, before we celebrate the 250th anniversary of the country on Saturday. Futures are higher after reports that the U.S. and Iran have agreed to halt hostilities, which we ... Here Are Monday’s Best Wall Street Analyst Research Calls: Adobe, Applovin, Casey’s General Stores, CrowdStrike, Honeywell Aerospace, Salesforce, Synaptics,
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.